A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

516

Participants

Timeline

Start Date

January 5, 2010

Primary Completion Date

June 9, 2011

Study Completion Date

July 27, 2012

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Mavrilimumab 10 mg

Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.

BIOLOGICAL

Mavrilimumab 30 mg

Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.

BIOLOGICAL

Mavrilimumab 50 mg

Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.

BIOLOGICAL

Mavrilimumab 100 mg

Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.

OTHER

Placebo

Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.

Trial Locations (55)

Unknown

Research Site, Plovdiv

Research Site, Sofia

Research Site, Varna

Research Site, Bruntál

Research Site, Ostrava - Trebovice

Research Site, Prague

Research Site, Praha 4 - Nusle

Research Site, Uherské Hradiště

Research Site, Zlín

Research Site, Tallinn

Research Site, Budapest

Research Site, Sopron

Research Site, Zalaegerszeg

Research Site, Chiba

Research Site, Chiyoda-ku

Research Site, Fukui-shi

Research Site, Fukuoka

Research Site, Goshogawara-shi

Research Site, Hamamatsu

Research Site, Iizuka-shi

Research Site, Kagoshima

Research Site, Kasama-shi

Research Site, Kitakyushu-shi

Research Site, Nagano

Research Site, Nagoya

Research Site, Okayama

Research Site, Omura-shi

Research Site, Sagamihara-shi

Research Site, Sasebo-shi

Research Site, Shinjuku-ku

Research Site, Liepāja

Research Site, Riga

Research Site, Valmiera

Research Site, Klaipėda

Research Site, Vilnius

Research Site, Bialystok

Research Site, Bydgoszcz

Research Site, Katowice

Research Site, Legnica

Research Site, Lublin

Research Site, Poznan

Research Site, Torun

Research Site, Warsaw

Research Site, Bucharest

Research Site, Ploieşti

Research Site, Târgu Mureş

Research Site, Barnaul

Research Site, Kazan'

Research Site, Kemerovo

Research Site, Novosibirsk

Research Site, Saint Petersburg

Research Site, Yaroslavl

Research Site, Donetsk

Research Site, Kiev

Research Site, Kyiv

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

MedImmune Ltd

INDUSTRY

lead

MedImmune LLC

INDUSTRY